Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Real-World Experience of Patients and Caregivers with Early-Line Treatment of Chronic Myeloid Leukemia in the US: A Retrospective 2-Year Social-Media Listening Analysis

Gaurav Vadnerkar, Joan Clements, Mel Mann, Vainavika Reddy Gaddam, Chaitali Nag, Shiva Padhi, David Wei, Marcello Azolino, Kejal Jadhav, Daisy Yang, Andrea Damon, Islam Sadek

Blood (2024) 144 (Supplement 1): 5192.

https://doi.org/10.1182/blood-2024-199951

Published: 2024

Journal Articles

Adverse Events and Treatment Adjustments Among Newly Diagnosed Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: A Comprehensive Data Analysis of Medicare Fee-for-Service and Commercial Plans in the United States

Elias Jabbour, David Wei, Hongbo Yang, Kejal Jadhav, Wei Song, Yajin Zhao, Anran Shao, Samantha Tomicki, Daisy Yang, Andrea Damon, Islam Sadek, Vamsi K. Kota

Blood (2024) 144 (Supplement 1): 2434.

https://doi.org/10.1182/blood-2024-201831

Published: 2024

Journal Articles

Treatment with Asciminib As a Second Line after One Prior Tyrosine Kinase Inhibitor (TKI) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) - a Chart Review Study in the United States

Ehab L. Atallah, Islam Sadek, David Wei, Dominick Latremouille-Viau, Carmine Rossi, Andrea Damon, Daisy Yang, Remi Bellefleur, Annie Guérin, Kejal Jadhav

Blood (2024) 144 (Supplement 1): 3812.

https://doi.org/10.1182/blood-2024-193201

Published: 2024

Journal Articles

Impact of Adverse Events on Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs) - Early Results of the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study

Kelly Schoenbeck, Joan Clements, Karen Demairo, David Wei, Nisha C Hazra, Cristina Constantinescu, Yan Meng, Dominick Latremouille-Viau, Kejal Jadhav, Courtney McDermott, Daisy Yang, Andrea Damon, Islam Sadek, Annie Guerin, Kathryn E. Flynn

Blood (2024) 144 (Supplement 1): 7913.

https://doi.org/10.1182/blood-2024-207213

Published: 2024

Journal Articles

Real-World Treatment Patterns and Molecular Response (MR) Among Patients with Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) in a Large Community Oncology Setting

Ira Zackon, April Beeks, David Wei, Chuck Wentworth, Jinhong Guo, Courtney McDermott, Kejal Jadhav, Lisa Herms, Andrea Damon, Islam Sadek, Christopher B. Benton

Blood (2024) 144 (Supplement 1): 6611.

https://doi.org/10.1182/blood-2024-210681

Published: 2024

Journal Articles

Patient, Caregiver, and Physician Perspectives on Communication in Diagnosing and Treating Higher-Risk Myelodysplastic Syndromes: A Qualitative Study

Melissa Culhane Maravic, Natalie Land, Nadya Prood, Kelly Birch, Claire Cagle, Suepattra G. May, Eduardo J. Sabate, Ngozi Afulezi, Teraneh Z. Jhaveri, Mindy Chen, Audrey Hassan, Islam Sadek, Cosmina Hogea

Blood (2023) 142 (Supplement 1): 5178.

https://doi.org/10.1182/blood-2023-181976

Published: 2023

Journal Articles

Machine Learning Approach to Understand Real-World Treatment in Patients with Higher-Risk Myelodysplastic Syndromes

Vandana Priya, Vivek P. Vaidya, Smita Agrawal, Neeraj Singh, Kaveri Chatra, Dhaval Parmar, Raymond Yan, Rahul K. Das, Mahnoush Haririfar, Peter McMahon, Mellissa Williamson, Islam Sadek, Cosmina Hogea

Blood (2023) 142 (Supplement 1): 5100.

https://doi.org/10.1182/blood-2023-182241

Published: 2023

Journal Articles

Evaluation of Disparities in Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patient Treatment Patterns in a Large US Health System

Kristin J. Moore, Nicole M. Engel-Nitz, Peter McMahon, Jason Beal, Teraneh Z. Jhaveri, Mellissa Williamson, Katherine Andrade, Christina Landis, Islam Sadek, Cosmina Hogea

Blood (2023) 142 (Supplement 1): 2434.

https://doi.org/10.1182/blood-2023-182031

Published: 2023

Journal Articles

Real-World Usage of Asciminib in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) in the United States (US) Using a Large Claims Database

Sudipto Mukherjee, Chi-Chang Chen, Magdaliz Gorritz, Islam Sadek, Serban Iorga, Zifan Zhou, Jing He, Rodrigo Maegawa, Andrea Damon, Germano Ferreira, Kejal Jadhav

Blood (2022) 140 (Supplement 1): 13297–13298.

https://doi.org/10.1182/blood-2022-166473

Published: 2022

Journal Articles

Treatments and Outcomes for Patients at Academic Cancer Centers with Myelodysplastic Syndrome (MDS) By Revised International Prognostic Scoring System (IPSS-R) Scores

Connor Willis, David A. Sallman, Malinda Tan, Madeline Brendle, Vonetta L. Williams, Craig Comperatore, Trang Au, Srinivas K. Tantravahi, Najla Al Ali, Jeffrey A. Gilreath, Tibor Kovacsovics, Xiting Cao, Islam Sadek, Rami S. Komrokji, David Stenehjem

Blood (2022) 140 (Supplement 1): 5291–5292.

https://doi.org/10.1182/blood-2022-162622

Published: 2022

Journal Articles

Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program

Blood (2021) 138 (Supplement 1): 4669.

https://doi.org/10.1182/blood-2021-145626

Published: 2021

Journal Articles

Effectiveness of Second-Line (2L) Tyrosine Kinase Inhibitor (TKI) Therapy after Resistance or Intolerance to a Prior TKI in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP)

Sudipto Mukherjee, MD PhD MPH, Xiting Cao, Islam Sadek, Rodrigo Maegawa, MD, Dominick Latremouille-Viau, MSc, Irina Pivneva, Annie Guérin, B. Douglas Smith, MD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-137079

Published: 2020

Journal Articles

Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd

Jerald P. Radich, MD, Richard A. Larson, MD, Hagop M. Kantarjian, MD, Michael W. Deininger, Javier Pinilla Ibarz, MD PhD, Daniel J. DeAngelo, MD PhD, Susan Branford, PhD FFSc (RCPA), Islam Sadek, Shalini Chaturvedi, Manu Sondhi, MD PhD, Matthew Wall, Kaushal Mishra, PhD, Das Purkayastha, PhD, Alok Shrestha, Vanessa Obourn, Brian S. White, Brian J. Druker

Blood (2019) 134 (Supplement_1): 665.

https://doi.org/10.1182/blood-2019-124716

Published: 2019

Journal Articles

Tyrosine Kinase Inhibitor Therapy Discontinuation in Clinical Practice in Chronic Myeloid Leukemia - a US Physician Survey Conducted after Guideline Updates

Ehab L. Atallah, MD, Islam Sadek, Xiting Cao, Dominick Latremouille-Viau, Irina Pivneva, PhD, Carmine Rossi, Annie Guerin, Vamsi Kota, MBBS

Blood (2019) 134 (Supplement_1): 2208.

https://doi.org/10.1182/blood-2019-125736

Published: 2019

Journal Articles

Social Media Network Utility in Disease Education: Experience from a CML-Disease Awareness Medical Education Program

Ehab L. Atallah, MD, Vamsi Kota, MBBS, Islam Sadek, Andrea Damon, PhD, Ji-May Jen, PharmD, Berna Cakmak, BPharm, Joshua Landy, MD FRCPC, Sharon Vorona, MBBS, Jerald P. Radich, MD

Blood (2019) 134 (Supplement_1): 5842.

https://doi.org/10.1182/blood-2019-124809

Published: 2019

Journal Articles

Myeloproliferative Neoplasms in Asia, Including Middle East, Turkey, and Algeria: Epidemiological Indices and Treatment Practice Patterns from the Multinational, Multicenter, Observational MERGE Registry

Mohamed A Yassin, Ali Taher, MD PhD, Vikram Mathews, MD, Hsin-An Hou, MD PhD, Tahir Shamsi, Tulin Tuglular, MD, Zhijian Xiao, Soo-Jeong Kim, MD, Depei Wu, MD PhD, Junmin Li, MD, Gerd Rippin, Islam Sadek, Asif Siddiqui, PhD, Raymond S Wong, MBChB, MD

Blood (2018) 132 (Supplement 1): 5461.

https://doi.org/10.1182/blood-2018-99-114416

Published: 2018

Journal Articles

Impact of Myeloproliferative Neoplasms (MPNs) on Health-Related Quality of Life (HRQOL) and Medical Resource Utilization: Results from the MERGE Registry

Ali Taher, MD PhD, Mohamed A Yassin, Zhijian Xiao, Hsin-An Hou, MD PhD, Tulin Tuglular, MD, Vikram Mathews, MD, Gerd Rippin, Islam Sadek, Asif Siddiqui, PhD, Raymond S Wong, MBChB, MD

Blood (2018) 132 (Supplement 1): 4311.

https://doi.org/10.1182/blood-2018-99-113248

Published: 2018

NARROW

Real-World Experience of Patients and Caregivers with Early-Line Treatment of Chronic Myeloid Leukemia in the US: A Retrospective 2-Year Social-Media Listening Analysis

Adverse Events and Treatment Adjustments Among Newly Diagnosed Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: A Comprehensive Data Analysis of Medicare Fee-for-Service and Commercial Plans in the United States

Treatment with Asciminib As a Second Line after One Prior Tyrosine Kinase Inhibitor (TKI) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) - a Chart Review Study in the United States

Impact of Adverse Events on Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs) - Early Results of the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study

Real-World Treatment Patterns and Molecular Response (MR) Among Patients with Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) in a Large Community Oncology Setting

Patient, Caregiver, and Physician Perspectives on Communication in Diagnosing and Treating Higher-Risk Myelodysplastic Syndromes: A Qualitative Study

Machine Learning Approach to Understand Real-World Treatment in Patients with Higher-Risk Myelodysplastic Syndromes

Evaluation of Disparities in Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patient Treatment Patterns in a Large US Health System

Real-World Usage of Asciminib in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) in the United States (US) Using a Large Claims Database

Treatments and Outcomes for Patients at Academic Cancer Centers with Myelodysplastic Syndrome (MDS) By Revised International Prognostic Scoring System (IPSS-R) Scores

Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program

Effectiveness of Second-Line (2L) Tyrosine Kinase Inhibitor (TKI) Therapy after Resistance or Intolerance to a Prior TKI in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP)

Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd

Tyrosine Kinase Inhibitor Therapy Discontinuation in Clinical Practice in Chronic Myeloid Leukemia - a US Physician Survey Conducted after Guideline Updates

Social Media Network Utility in Disease Education: Experience from a CML-Disease Awareness Medical Education Program

Myeloproliferative Neoplasms in Asia, Including Middle East, Turkey, and Algeria: Epidemiological Indices and Treatment Practice Patterns from the Multinational, Multicenter, Observational MERGE Registry

Impact of Myeloproliferative Neoplasms (MPNs) on Health-Related Quality of Life (HRQOL) and Medical Resource Utilization: Results from the MERGE Registry

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only